1. Livmorkreft (endometriecancer)

Aalders, J., Abeler, V., Kolstad, P., & Onsrud, M. (1980). Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstetrics and Gynecology, 56(4), 419-27.

Aaltonen, L., Johns, L., Järvinen, H., Mecklin, J. P., & Houlston, R. (2007). Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clinical Cancer Research, 13(1), 356-61.

Abeler, V. M., & Kjørstad, K. E. (1991). Endometrial adenocarcinoma in Norway. A study of a total population. Cancer, 67(12), 3093-103.

Albrektsen, G., Heuch, I., Wik, E., & Salvesen, H. B. (2009). Parity and time interval since childbirth influence survival in endometrial cancer patients. International Journal of Gynecological Cancer, 19(4), 665-9.

Ali, A. T. (2014). Reproductive factors and the risk of endometrial cancer. International Journal of Gynecological Cancer, 24(3), 384-93.

Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., & Vergote, I. (2005). Endometrial cancer. Lancet, 366(9484), 491-505.

Anggraeni, T. D., Al Fattah, A. N., & Surya, R. (2018). Prophylactic salpingectomy and ovarian cancer: An evidence-based analysis. South Asian journal of cancer, 7(1), 42-45.

Anonym (1987). Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA, 257(6), 796-800.

Baiocchi, G., Andrade, C., Ribeiro, R., Moretti-Marques, R., Tsunoda, A. T., Alvarenga-Bezerra, V., Lopes, A., Costa, R. L. R., ... Goncalves, B. T. (2022). Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial). International Journal of Gynecological Cancer, 32(5), 676-679.

Ballester, M., Dubernard, G., Lécuru, F., Heitz, D., Mathevet, P., Marret, H., Querleu, D., Golfier, F., ... Daraï, E. (2011). Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncology, 12(5), 469-76.

Banno, K., Yanokura, M., Kobayashi, Y., Kawaguchi, M., Nomura, H., Hirasawa, A., Susumu, N., & Aoki, D. (2009). Endometrial cancer as a familial tumor: pathology and molecular carcinogenesis (review). Current genomics, 10(2), 127-32.

Barakat, R. R., Bundy, B. N., Spirtos, N. M., Bell, J., & Mannel, R. S. (2006). Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology, 24(4), 587-92.

Barlin, J. N., Khoury-Collado, F., Kim, C. H., Leitao, M. M. ,. J., Chi, D. S., Sonoda, Y., Alektiar, K., DeLair, D. F., ... Abu-Rustum, N. R. (2012). The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecologic Oncology, 125(3), 531-5.

Barrow, E., Robinson, L., Alduaij, W., Shenton, A., Clancy, T., Lalloo, F., Hill, J., & Evans, D. G. (2009). Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 75(2), 141-9.

Berek, J. S., Matias-Guiu, X., Creutzberg, C., Fotopoulou, C., Gaffney, D., Kehoe, S., Lindemann, K., Mutch, D., & Concin, N. (2023). FIGO staging of endometrial cancer: 2023. International Journal of Gynaecology and Obstetrics, 162(2), 383-394.

Bestvina, C. M., & Fleming, G. F. (2016). Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. The oncologist, 21(10), 1250-1259.

Bogani, G., Mariani, A., Paolini, B., Ditto, A., & Raspagliesi, F. (2019). Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells. Gynecologic Oncology, 153(3), 670-675.

Bogani, G., Giannini, A., Vizza, E., Di Donato, V., & Raspagliesi, F. (2024). Sentinel node mapping in endometrial cancer. Journal of Gynecologic Oncology, 35(1), e29.

Bollineni, V. R., Ytre-Hauge, S., Bollineni-Balabay, O., Salvesen, H. B., & Haldorsen, I. S. (2016). High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature. Journal of Nuclear Medicine, 57(6), 879-85.

Bonadona, V., Bonaïti, B., Olschwang, S., Grandjouan, S., Huiart, L., Longy, M., Guimbaud, R., Buecher, B., ... Bonaiti-Pellie, C. (2011). Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA, 305(22), 2304-10.

Buza, N. (2021). HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. International Journal of Gynecological Pathology, 40(1), 17-23.

Canadian Cancer Trials Group (2022-2029). Adjuvant Therapy in POLE-Mutated and p53-Wildtype/​NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER [pågående studie] (NCT05640999). Hentet fra https://clinicaltrials.gov/study/NCT05640999

Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A. D., Akbani, R., Liu, Y., Shen, H., Robertson, A. G., ... Levine, D. A. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497(7447), 67-73.

Casey, L., & Singh, N. (2021). POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting. International Journal of Gynecological Pathology, 40(1), 5-16.

Colombo, N., Preti, E., Landoni, F., Carinelli, S., Colombo, A., Marini, C., & Sessa, C. (2013). Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24 Suppl 6, vi33-8.

Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martin, A., Ledermann, J., Marth, C., Nout, R., ... Sessa, C. (2016). ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. International Journal of Gynecological Cancer, 26(1), 2-30.

Committee on Gynecologic Practice (2014). Tamoxifen and uterine cancer (Committee Opinion no 601). Washington, DC: American College of Obstetricians and Gynecologists. Hentet fra http://www.acog.org/-/media/Committee-Opinions/Committee-on-Gynecologic-Practice/co601.pdf?dmc=1&ts=20150203T1931301384

Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., ... Creutzberg, C. L. (2021). ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 31(1), 12-39.

Concin, N., Matias-Guiu, X., Cibula, D., Colombo, N., Creutzberg, C. L., Ledermann, J., Mirza, M. R., Vergote, I., ... Nout, R. A. (2025). ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncology, 26(8), e423-e435.

Crean-Tate, K. K., Faubion, S. S., Pederson, H. J., Vencill, J. A., & Batur, P. (2020). Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. American Journal of Obstetrics and Gynecology, 222(2), 103-113.

Creutzberg, C. L., van Putten, W. L., Koper, P. C., Lybeert, M. L., Jobsen, J. J., Warlam-Rodenhuis, C. C., De Winter, K. A., Lutgens, L. C., ... van Lent, M. (2000). Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet, 355(9213), 1404-11.

Crosbie, E. J., Ryan, N. A. J., Arends, M. J., Bosse, T., Burn, J., Cornes, J. M., Crawford, R., Eccles, D., ... Evans, D. G. (2019). The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 21(10), 2390-2400.

Cusimano, M. C., Vicus, D., Pulman, K., Maganti, M., Bernardini, M. Q., Bouchard-Fortier, G., Laframboise, S., May, T., ... Ferguson, S. E. (2021). Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging. JAMA Surgery, 156(2), 157-164.

De Vitis, L. A., Fumagalli, D., Schivardi, G., Capasso, I., Grcevich, L., Multinu, F., Cucinella, G., Occhiali, T., ... Glaser, G. (2024). Incidence of sentinel lymph node metastases in apparent early-stage endometrial cancer: a multicenter observational study. International Journal of Gynecological Cancer, 34(5), 689-696.

de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., ... Creutzberg, C. L. (2019). Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology, 20(9), 1273-1285.

Di Donato, V., Palaia, I., D'Aniello, D., Musacchio, L., Santangelo, G., Di Mauro, F., Di Pinto, A., Musella, A., ... Benedetti Panici, P. (2020). Does Hormone Replacement Therapy Impact the Prognosis in Endometrial Cancer Survivors? A Systematic Review. Oncology, 98(4), 195-201.

Doherty, J. A., Cushing-Haugen, K. L., Saltzman, B. S., Voigt, L. F., Hill, D. A., Beresford, S. A., Chen, C., & Weiss, N. S. (2007). Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. American Journal of Obstetrics and Gynecology, 197(2), 139.e1-7.

Dossus, L., Allen, N., Kaaks, R., Bakken, K., Lund, E., Tjonneland, A., Olsen, A., Overvad, K., ... Riboli, E. (2010). Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 127(2), 442-51.

Dowty, J. G., Win, A. K., Buchanan, D. D., Lindor, N. M., Macrae, F. A., Clendenning, M., Antill, Y. C., Thibodeau, S. N., ... Jenkins, M. A. (2013). Cancer risks for MLH1 and MSH2 mutation carriers. Human Mutation, 34(3), 490-7.

Duska, L. R., Garrett, A., Rueda, B. R., Haas, J., Chang, Y., & Fuller, A. F. (2001). Endometrial cancer in women 40 years old or younger. Gynecologic Oncology, 83(2), 388-93.

Ethier, J. L., Desautels, D. N., Amir, E., & MacKay, H. (2017). Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecologic Oncology, 147(1), 158-166.

Evans-Metcalf, E. R., Brooks, S. E., Reale, F. R., & Baker, S. P. (1998). Profile of women 45 years of age and younger with endometrial cancer. Obstetrics and Gynecology, 91(3), 349-54.

Fader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., Chambers, S., Secord, A. A., ... Santin, A. D. (2020). Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research, 26(15), 3928-3935.

Fasmer, K. E., Hodneland, E., Dybvik, J. A., Wagner-Larsen, K., Trovik, J., Salvesen, Ø., Krakstad, C., & Haldorsen, I. H. S. (2021). Whole-Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer. Journal of Magnetic Resonance Imaging, 53(3), 928-937.

Fu, Y., & Zhuang, Z. (2014). Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. International Journal of Clinical and Experimental Pathology, 7(10), 6419-29.

Fung-Kee-Fung, M., Dodge, J., Elit, L., Lukka, H., Chambers, A., Oliver, T., the Gynecology Cancer Disease Site Group (2006). Follow-up after primary therapy for endometrial cancer (Evidence-based Series 4-9 IN REVIEW). Toronto (ON): Program in Evidence-based Care og Cancer Care Ontario. Hentet fra https://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc4-9f.pdf

Galaal, K., Bryant, A., Fisher, A. D., Al-Khaduri, M., Kew, F., & Lopes, A. D. (2012). Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database of Systematic Reviews, (9), CD006655.

Gallos, I. D., Yap, J., Rajkhowa, M., Luesley, D. M., Coomarasamy, A., & Gupta, J. K. (2012). Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology, 207(4), 266.e1-12.

Gómez-Hidalgo, N. R., Ramirez, P. T., Ngo, B., Pérez-Hoyos, S., Coreas, N., Sanchez-Iglesias, J. L., Cabrera, S., Franco, S., ... Gil-Moreno, A. (2020). Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis. Clinical & Translational Oncology, 22(8), 1272-1279.

Goodfellow, P. J., Billingsley, C. C., Lankes, H. A., Ali, S., Cohn, D. E., Broaddus, R. J., Ramirez, N., Pritchard, C. C., ... Mutch, D. (2015). Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Journal of Clinical Oncology, 33(36), 4301-8.

Grassi, T., Mariani, A., Cibula, D., Soliman, P. T., Suman, V. J., Weaver, A. L., Pedra Nobre, S., Weigelt, B., ... Abu-Rustum, N. R. (2020). A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial). International Journal of Gynecological Cancer, 30(10), 1627-1632.

Hagen, B., Valla, M., Aune, G., Ravlo, M., Abusland, A. B., Araya, E., Sundset, M., & Tingulstad, S. (2016). Indocyanine green fluorescence imaging of lymph nodes during robotic-assisted laparoscopic operation for endometrial cancer. A prospective validation study using a sentinel lymph node surgical algorithm. Gynecologic Oncology, 143(3), 479-483.

Haldorsen, I. S., & Salvesen, H. B. (2016). What Is the Best Preoperative Imaging for Endometrial Cancer?. Current Oncology Reports, 18(4), 25.

Hampel, H., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., Comeras, I., LaJeunesse, J., Nakagawa, H., ... Vaccarello, L. (2007). Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Research, 67(19), 9603.

Harkenrider, M. M., Martin, B., Nieto, K., Small, C., Aref, I., Bergman, D., Chundury, A., Elshaikh, M. A., ... Small, W. ,. J. (2018). Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma. International Journal of Radiation Oncology, Biology, Physics, 101(5), 1069-1077.

Harris, H. R., & Terry, K. L. (2016). Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertility Research and Practice, 2, 14.

Heald, B., Mester, J., Rybicki, L., Orloff, M. S., Burke, C. A., & Eng, C. (2010). Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology, 139(6), 1927-33.

Jamieson, A., Grube, M., Leung, S., Chiu, D., Lum, A., Kwon, J. S., Talhouk, A., Gilks, B., ... McAlpine, J. N. (2024). Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion. International Journal of Gynecological Cancer, 34(4), 544-549.

Janda, M., Gebski, V., Davies, L. C., Forder, P., Brand, A., Hogg, R., Jobling, T. W., Land, R., ... Obermair, A. (2017). Effect of Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women With Stage I Endometrial Cancer: A Randomized Clinical Trial. JAMA, 317(12), 1224-1233.

Jerzak, K. J., Duska, L., & MacKay, H. J. (2019). Endocrine therapy in endometrial cancer: An old dog with new tricks. Gynecologic Oncology, 153(1), 175-183.

Johnson, N., Bryant, A., Miles, T., Hogberg, T., & Cornes, P. (2011). Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database of Systematic Reviews, (10), CD003175.

Kaban, A., Topuz, S., Erdem, B., Sozen, H., Numanoğlu, C., & Salihoğlu, Y. (2018). Is Omentectomy Necessary for Non-Endometrioid Endometrial Cancer. Gynecologic and Obstetric Investigation, 83(5), 482-486.

Kim, C. H., Khoury-Collado, F., Barber, E. L., Soslow, R. A., Makker, V., Leitao, M. M. ,. J., Sonoda, Y., Alektiar, K. M., ... Abu-Rustum, N. R. (2013). Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecologic Oncology, 131(3), 714-9.

Kinjyo, Y., Kudaka, W., Ooyama, T., Inamine, M., Nagai, Y., & Aoki, Y. (2015). Ovarian preservation in young women with endometrial cancer of endometrioid histology. Acta Obstetricia et Gynecologica Scandinavica, 94(4), 430-4.

Knab, D. R. (1977). Estrogen and endometrial carcinoma. Obstetrical and Gynecological Survey, 32(5), 267-81.

Köbel, M., Ronnett, B. M., Singh, N., Soslow, R. A., Gilks, C. B., & McCluggage, W. G. (2019). Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. International Journal of Gynecological Pathology, 38(Suppl 1), S123-131.

Kong, A., Johnson, N., Kitchener, H. C., & Lawrie, T. A. (2012). Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database of Systematic Reviews, (4), CD003916.

Koornstra, J. J., Mourits, M. J., Sijmons, R. H., Leliveld, A. M., Hollema, H., & Kleibeuker, J. H. (2009). Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncology, 10(4), 400-8.

Larsen, I. K. (2018). Cancer in Norway 2017: cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Larsen, I. K. (2025). Cancer in Norway 2024: Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway / Norwegian Institute of Public Health.

Lau, H. Y., Chen, M. Y., Ke, Y. M., Chen, J. R., Chen, I. H., Liou, W. S., Fu, H. C., Chang, C. C., ... Wang, K. L. (2015). Outcome of ovarian preservation during surgical treatment for endometrial cancer: A Taiwanese Gynecologic Oncology Group study. Taiwanese Journal of Obstetrics & Gynecology, 54(5), 532-6.

Lee, B., Suh, D. H., Kim, K., No, J. H., & Kim, Y. B. (2016). Influence of positive peritoneal cytology on prognostic factors and survival in early-stage endometrial cancer: a systematic review and meta-analysis. Japanese Journal of Clinical Oncology, 46(8), 711-7.

Leitao, M. M. ,. J., Kehoe, S., Barakat, R. R., Alektiar, K., Gattoc, L. P., Rabbitt, C., Chi, D. S., Soslow, R. A., & Abu-Rustum, N. R. (2009). Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecologic Oncology, 113(1), 105-8.

Liu, T., Tu, H., Li, Y., Liu, Z., Liu, G., & Gu, H. (2019). Impact of Radical Hysterectomy Versus Simple Hysterectomy on Survival of Patients with Stage 2 Endometrial Cancer: A Meta-analysis. Annals of Surgical Oncology, 26(9), 2933-2942.

Luo, J., Beresford, S., Chen, C., Chlebowski, R., Garcia, L., Kuller, L., Regier, M., Wactawski-Wende, J., & Margolis, K. L. (2014). Association between diabetes, diabetes treatment and risk of developing endometrial cancer. British Journal of Cancer, 111(7), 1432-9.

Lyu, T., Guo, L., Chen, X., Jia, N., Gu, C., Zhu, M., Zhao, Y., Liu, X., & Feng, W. (2019). Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study. The Journal of international medical research, 47(6), 2492-2498.

Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., ... Casado Herraez, A. (2020). Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. Journal of Clinical Oncology, 38(26), 2981-2992.

Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., ... Taylor, M. (2019). Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncology, 20(5), 711-718.

Martin-Hirsch, P. P., Bryant, A., Keep, S. L., Kitchener, H. C., & Lilford, R. (2011). Adjuvant progestagens for endometrial cancer. Cochrane Database of Systematic Reviews, (6), CD001040.

Matei, D., Filiaci, V., Randall, M. E., Mutch, D., Steinhoff, M. M., DiSilvestro, P. A., Moxley, K. M., Kim, Y. M., ... Miller, D. S. (2019). Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. New England Journal of Medicine, 380(24), 2317-2326.

Matsuo, K., Yabuno, A., Hom, M. S., Shida, M., Kakuda, M., Adachi, S., Mandelbaum, R. S., Ueda, Y., ... Roman, L. D. (2018). Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. Gynecologic Oncology, 149(2), 301-309.

Miller, D., Filiaci, V., Fleming, G., Mannel, R., Cohn, D., Matsumoto, T., Tewari, K., DiSilvestro, P., ... Zaino, R. (2012). Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A gynecologic oncology group study. Gynecologic Oncology, 125(3), 771.

Miller, D. S., Filiaci, V. L., Mannel, R. S., Cohn, D. E., Matsumoto, T., Tewari, K. S., DiSilvestro, P., Pearl, M. L., ... Fleming, G. F. (2020). Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). Journal of Clinical Oncology, 38(33), 3841-3850.

Mills, A. M., Liou, S., Ford, J. M., Berek, J. S., Pai, R. K., & Longacre, T. A. (2014). Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. American Journal of Surgical Pathology, 38(11), 1501-9.

Minig, L., Franchi, D., Boveri, S., Casadio, C., Bocciolone, L., & Sideri, M. (2011). Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Annals of Oncology, 22(3), 643-649.

Mirza, M. R., Chase, D. M., Slomovitz, B. M., dePont Christensen, R., Novák, Z., Black, D., Gilbert, L., Sharma, S., ... Powell, M. A. (2023). Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. New England Journal of Medicine, 388(23), 2145-2158.

Moore, T. D., Phillips, P. H., Nerenstone, S. R., & Cheson, B. D. (1991). Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. Journal of Clinical Oncology, 9(6), 1071-88.

Møller, P., Seppälä, T. T., Bernstein, I., Holinski-Feder, E., Sala, P., Gareth Evans, D., Lindblom, A., Macrae, F., ... Capella, G. (2018). Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 67(7), 1306-1316.

NCCN (2020). Genetic/Familial High-Risk Assessment: Colorectal. [NCCN Guideline]. Version 1 Plymouth Meeting, PA: National Comprehensive Cancer Network.

NorPreM (2024). Nasjonal initiativ for å fremme presisjonsdiagnostikk innenfor gynekologisk kreft [s.l.]: Nasjonalt kompetansenettverk for persontilpasset medisin. Hentet fra https://norprem.no/wp-content/uploads/2024/11/Gyn.kreft-rapport-ferdigstilt.pdf

Nye metoder (23.01.2023). Dostarlimab (Jemperli) (ID2020_086). [nettdokument]. Oslo: Nye metoder. Hentet 09.12.2025 fra https://www.nyemetoder.no/metoder/dostarlimab-jemperli/

Nye metoder (12.02.2024). Dostarlimab (Jemperli) - Indikasjon II ID2023_082. [nettdokument]. Oslo: Nye metoder. Hentet 27.12.2024 fra https://www.nyemetoder.no/metoder/dostarlimab-jemperli-indikasjon-ii/

Nye metoder (10.02.2025). Dostarlimab (Jemperli) - ID2024_060. [nettdokument]. Oslo: Nye metoder. Hentet 27.12.2025 fra https://www.nyemetoder.no/metoder/id2024_060/

Obermair, A., Nicklin, J., Gebski, V., Hayes, S. C., Graves, N., Mileshkin, L., Lin, M. Y., Beale, P., ... Janda, M. (2021). A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020. International Journal of Gynecological Cancer, 31(12), 1595-1601.

Park, J. Y., Kim, D. Y., Kim, J. H., Kim, Y. M., Kim, K. R., Kim, Y. T., Seong, S. J., Kim, T. J., ... Nam, J. H. (2013). Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). European Journal of Cancer, 49(4), 868-74.

Pecorelli, S. (2009). Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. International Journal of Gynaecology and Obstetrics, 105(2), 103-4.

Pike, M. C., Peters, R. K., Cozen, W., Probst-Hensch, N. M., Felix, J. C., Wan, P. C., & Mack, T. M. (1997). Estrogen-progestin replacement therapy and endometrial cancer. Journal of the National Cancer Institute, 89(15), 1110-6.

Pilarski, R., Stephens, J. A., Noss, R., Fisher, J. L., & Prior, T. W. (2011). Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. Journal of Medical Genetics, 48(8), 505-12.

Plante, M., Stanleigh, J., Renaud, M. C., Sebastianelli, A., Grondin, K., & Grégoire, J. (2017). Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?. Gynecologic Oncology, 146(2), 240-246.

Randall, M. E., Filiaci, V., McMeekin, D. S., von Gruenigen, V., Huang, H., Yashar, C. M., Mannel, R. S., Kim, J. W., ... Miller, D. S. (2019). Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. Journal of Clinical Oncology, 37(21), 1810-1818.

Rodolakis, A., Biliatis, I., Morice, P., Reed, N., Mangler, M., Kesic, V., & Denschlag, D. (2015). European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients. International Journal of Gynecological Cancer, 25(7), 1258-65.

Rose, P. G. (1996). Endometrial carcinoma. New England Journal of Medicine, 335(9), 640-9.

Rossi, E. C., Kowalski, L. D., Scalici, J., Cantrell, L., Schuler, K., Hanna, R. K., Method, M., Ade, M., ... Boggess, J. F. (2017). A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncology, 18(3), 384-392.

Ryan, N. A. J., McMahon, R., Tobi, S., Snowsill, T., Esquibel, S., Wallace, A. J., Bunstone, S., Bowers, N., ... Crosbie, E. J. (2020). The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. PLoS Medicine, 17(9), e1003263.

Salvesen, H. B., Akslen, L. A., Iversen, T., & Iversen, O. E. (1997). Recurrence of endometrial carcinoma and the value of routine follow up. British Journal of Obstetrics and Gynaecology, 104(11), 1302-7.

Salvesen, H. B., Iversen, O. E., & Akslen, L. A. (1999). Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. Journal of Clinical Oncology, 17(5), 1382-90.

Salvesen, H. B., Haldorsen, I. S., & Trovik, J. (2012). Markers for individualised therapy in endometrial carcinoma. Lancet Oncology, 13(8), e353-61.

Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. B., Daniels, M. S., White, K. G., ... Lu, K. H. (2006). Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. New England Journal of Medicine, 354(3), 261-9.

Seagle, B. L., Alexander, A. L., Lantsman, T., & Shahabi, S. (2018). Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database. American Journal of Obstetrics and Gynecology, 218(3), 329.e1-329.e15.

Talhouk, A., McConechy, M. K., Leung, S., Yang, W., Lum, A., Senz, J., Boyd, N., Pike, J., ... McAlpine, J. N. (2017). Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer, 123(5), 802-813.

Thigpen, J. T., Brady, M. F., Homesley, H. D., Malfetano, J., DuBeshter, B., Burger, R. A., & Liao, S. (2004). Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. Journal of Clinical Oncology, 22(19), 3902-8.

Trovik, J., Wik, E., Werner, H. M., Krakstad, C., Helland, H., Vandenput, I., Njolstad, T. S., Stefansson, I. M., ... Salvesen, H. B. (2013). Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer, 49(16), 3431-41.

Vale, C. L., Tierney, J., Bull, S. J., & Symonds, P. R. (2012). Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database of Systematic Reviews, (8), CD003915.

van Weelden, W. J., Massuger, L., Pijnenborg, J. M. A., & Romano, A. (2019). Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review. Frontiers in Oncology, 9, 359.

Vergote, I., Kjørstad, K., Abeler, V., & Kolstad, P. (1989). A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer, 64(5), 1011-6.

Vistad, I. (2019-2030). The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study (LETSGO) [pågående studie]. (NCT04122235). Hentet fra https://clinicaltrials.gov/study/NCT04122235

Walker, J. L., Piedmonte, M. R., Spirtos, N. M., Eisenkop, S. M., Schlaerth, J. B., Mannel, R. S., Spiegel, G., Barakat, R., ... Sharma, S. K. (2009). Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. Journal of Clinical Oncology, 27(32), 5331-6.

Wang, Y., Wang, Y., Li, J., Cragun, J., Hatch, K., Chambers, S. K., & Zheng, W. (2013). Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium. Journal of Hematology & Oncology, 6, 22.

Weiderpass, E., Baron, J. A., Adami, H. O., Magnusson, C., Lindgren, A., Bergstrom, R., Correia, N., & Persson, I. (1999). Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet, 353(9167), 1824-8.

Westin, S. N., Moore, K., Chon, H. S., Lee, J. Y., Thomes Pepin, J., Sundborg, M., Shai, A., de la Garza, J., ... Van Nieuwenhuysen, E. (2024). Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. Journal of Clinical Oncology, 42(3), 283-299.

WHO Classification of Tumours Editorial Board (2020). Female Genital Tumours. International Agency for Research on Cancer.

Wijnen, J., de Leeuw, W., Vasen, H., van der Klift, H., Moller, P., Stormorken, A., Meijers-Heijboer, H., Lindhout, D., ... Fodde, R. (1999). Familial endometrial cancer in female carriers of MSH6 germline mutations. Nature Genetics, 23(2), 142-4.

Yamazawa, K., Hirai, M., Fujito, A., Nishi, H., Terauchi, F., Ishikura, H., Shozu, M., & Isaka, K. (2007). Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Human Reproduction, 22(7), 1953-8.

Ytre-Hauge, S., Husby, J. A., Magnussen, I. J., Werner, H. M., Salvesen Ø, O., Bjørge, L., Trovik, J., Stefansson, I. M., ... Haldorsen, I. S. (2015). Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. International Journal of Gynecological Cancer, 25(3), 459-66.

Zhang, Y., Liu, H., Yang, S., Zhang, J., Qian, L., & Chen, X. (2014). Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. International Journal of Biological Markers, 29(1), e21-9.